Shortly after the release of Canada's long-awaited final guidelines for the implementation of its International Reference Pricing (IRP) system reform, The analyst reflects on how the final reform compares to the original plans and where the real danger to the pharma industry lies as the new rules take effect.
Table of Contents
- Key findings
- The history of a much-delayed IRP reform
- Role of IRP in pricing process
- An unexpected positive for pharma in the final guidelines
- Disclaimer
